Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation

Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation
Dr Shivali Gulab, CEO of Avalia Immunotherapies. (Image: Avalia)
Riley Kennedy
Liquidators have been appointed to a biotech outfit that helped produce a covid-19 vaccine after it failed to raise cash to help further its other project.Founded in 2015, Avalia Immunotherapies was a preclinical-stage biotech company attempting to develop a fully synthetic vaccine and immunotherapy platform. Its lead programme was targeting a functional cure for chronic Hepatitis B.After it couldn’t raise further funding for clinical development, Baker Tilly Staples Rodway’s Tony Maginness and Jared Booth were appointed liquid...

More Finance

Surcharge ban may not be a win for consumers
Finance

Peter Griffin: Surcharge ban may not be a win for consumers

There are winners and losers in the surcharge move.

Peter Griffin 30 Jul 2025
FNZ employee shareholders stake claim at $7.7b
Finance

FNZ employee shareholders stake claim at $7.7b

The claim has been lodged in the High Court at Wellington.

Victoria Young 29 Jul 2025
FMA warns lenders on mortgage fraud
Finance

FMA warns lenders on mortgage fraud

The FMA sees dangers for borrowers if lenders aren't vigilant.

Staff reporters 25 Jul 2025
‘Teflon Man’ Neil Quigley’s next big job
Finance Analysis

Pattrick Smellie: ‘Teflon Man’ Neil Quigley’s next big job

Is the RBNZ lining up a Canadian replacement for Adrian Orr?

Pattrick Smellie 23 Jul 2025